BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190723
DTEND;VALUE=DATE:20190726
DTSTAMP:20260515T001305
CREATED:20190404T071545Z
LAST-MODIFIED:20190404T071545Z
UID:20177-1563840000-1564099199@www.pharmajournalist.com
SUMMARY:2nd Neuropsychiatric Drug Development Summit
DESCRIPTION:THE INDUSTRY’S DEFINITIVE MEETING TO ADVANCE THE DEVELOPMENT OF CLINICALLY TRANSFORMATIVE NEUROPSYCHIATRIC DRUGS \n \nWith the huge unmet clinical need in neuropsychiatry and despite multiple approved pharmaceuticals available\, the development of the next generation of neuropsychiatric drugs is essential. \nThe abundance of excitement and scientific progress in the field – especially with the recent approval of esketamine – will be captured at the Neuropsychiatric Drug Development summit\, in Boston on July 23 – 25\, 2019. \nBuilt with thought-leaders at Sage Therapeutics\, Johnson & Johnson and Lundbeck\, the 2nd Annual NPD summit will unravel the complexities of developing truly clinically transformative neuropsychiatric drugs. \nDedicated to overcoming challenges in neuropsychiatric drug development\, this comprehensive discussion and networking forum will cover: \n\nReviewing the current clinical landscape to share learned lessons\, predict potential success and identify future opportunities\nDetermine what we can expect from neuropsychiatric preclinical models to better predict clinical efficacy\nUtilize what we know from the clinical to improve our use of translational strategies\nDiscuss the potential for digital therapeutics to transform the success of efficacious pharmaceuticals\nReview symptomatic focused drug development to identify the benefits and impact future regulation\nEvaluate the potential for different neuropsychiatric targets by improving our understanding of neuropsychiatric biology\nImproving our understanding of the role of genetics in neuropsychiatry and debating the future of precision medicine for neuropsychiatric disorders\n\nJoin your peers at NPD to be part of the cross-industry discussion on latest developments\, insights and science to elevate clinically effective neuropsychiatric therapeutic pipelines \nTo learn more about this event\, visit https://ter.li/belugv
URL:https://www.pharmajournalist.com/event/2nd-neuropsychiatric-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR